Journal list Promote Sponsor
verified SJR 2,885 · Q1 • database Scopus / SJR & Web of Science indexed
Biochimica et Biophysica Acta - Reviews on Cancer
Netherlands · Elsevier B.V.
workspace_premium Q1 — Genetics lock_open Open Access

Biochimica et Biophysica Acta - Reviews on Cancer

Biochimica et Biophysica Acta - Reviews on Cancer is a journal indexed in SJR in Genetics and Oncology with an H index of 166. It has an SJR impact factor of 2,885 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,885.

Biochimica et Biophysica Acta - Reviews on Cancer focuses its scope in these topics and keywords: cell, role, cancer, defects, resistance, therapeutic, progressionthe, nichespyruvate, tumorigenesis, krasinitiated, ...

ISSN: 0304-419X
Publisher: Elsevier B.V.
Category: Genetics
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
2,885 Q1
H-index 166
Acceptance rate pie_chart
22% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
NPD Open Access
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

2,885

H-index

166

Docs (year)

162

Docs 3y

440

Total refs

28357

Cites 3y

4789

Citable 3y

437

Cites/Doc 2y

8.92

Ref/Doc

175.04

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

CSH Meeting on Cancer Genetics 1998

View more

Viral infection-oxidative stress/DNA damage-aberrant DNA methylation: separate or interrelated events responsible for genetic instability and childhood ALL development?

View more

Gastrins, cholecystokinins and gastrointestinal cancer

View more

Functional role for the c-Abl protein tyrosine kinase in the cellular response to genotoxic stress

View more

Extracellular vesicles in gastrointestinal cancer in conjunction with microbiota: On the border of Kingdoms

View more

Erratum to 'Molecular horizons of cancer therapeutics. 11th Pezcoller Symposium'

View more

Epigenetic diversity in hematopoietic neoplasms

View more

Emerging applications for phospho-proteomics in cancer molecular therapeutics

View more

EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors

View more

Editorial

View more

DNA Repair: Bacteria to Humans

View more

DNA methylation: regulation of gene expression and role in the immune system

View more
SHOW MORE ARTICLES

DNA damage-induced apoptosis: insights from the mouse

View more

3rd Geneva aging workshop 2002: cancer, apoptosis and aging

View more

Control of the higher eukaryote cell cycle by p34cdc2 homologues

View more

Clonal origin of human tumors

View more

Cigarette smoking, cyclooxygenase-2 pathway and cancer

View more

Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites

View more

CAK in TFIIH: crucial connection or confounding coincidence?

View more

Biological functions of hyaluronan and cytokine-inducible deubiquitinating enzymes

View more

Autologous bone-marrow transplantation in Non-Hodgkin's lymphomas

View more

Angiogenesis: from understanding to targeting

View more

An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro

View more

An analysis of the role of tRNA species as primers for the transcription into DNA of RNA tumor virus genomes

View more

FAQs